{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T09:46:42Z","timestamp":1793699202413,"version":"4.5.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T00:00:00Z","timestamp":1778025600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T00:00:00Z","timestamp":1778025600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004737","name":"National Health Research Institutes","doi-asserted-by":"publisher","award":["NHRI-EX112-11220BI"],"award-info":[{"award-number":["NHRI-EX112-11220BI"]}],"id":[{"id":"10.13039\/501100004737","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004737","name":"National Health Research Institutes","doi-asserted-by":"publisher","award":["NHRI-EX113-11220BI"],"award-info":[{"award-number":["NHRI-EX113-11220BI"]}],"id":[{"id":"10.13039\/501100004737","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2026,8,20]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Colorectal cancer (CRC) is a disease leading cause of death worldwide. Lacking molecular markers for early detection and suitable candidates for targeted therapies are two main reasons for causing CRC malignancy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Exploring the role of NUDT21 in colorectal cancer metastasis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A systematic bioinformatic analysis identified key genes involved in colorectal cancer, which were subsequently validated through loss-of-function and gain-of-function experiments conducted both in vitro and in vivo.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Overexpression of nucleoside diphosphate linked moiety X hydrolases-type motif 21 (NUDT21), a critical factor that regulates alternative polyadenylation, is observed in malignant polyps and in human and mouse CRC. Survival analysis reveals that high level of NUDT21 is associated with poor prognosis. NUDT21 knockdown not only inhibits cell growth but also reduces malignancy traits like anchorage-independent growth and cancer stemness. RNA-seq and RIP-seq results show NUDT21 preferentially binds to the proximal alternative polyadenylation site of numerous oncogenes to promote their expression and thus drive the progression of CRC. Treatment with re-purposing drugs targeting NUDT21 exhibit therapeutic potential in cell culture, organoid, orthotopic, and patient-derived xenografted CRC models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These findings demonstrate that NUDT21 is a critical regulator of colon cancer progression and a promising therapeutic target for CRC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1038\/s41416-026-03451-9","type":"journal-article","created":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T02:52:55Z","timestamp":1778035975000},"page":"518-531","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Targeting NUDT21-mediated alternative polyadenylation of oncogenes ameliorates colorectal cancer malignancy and metastasis"],"prefix":"10.1038","volume":"135","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9967-5037","authenticated-orcid":false,"given":"Shih-Chieh","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya-Chuan","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jui-Lin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsian-Jean","family":"Chin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ching-Chin","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin-Chih","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6574-6952","authenticated-orcid":false,"given":"Yi-Syuan","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo-Wen","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaw-Jenq","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,6]]},"reference":[{"key":"3451_CR1","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1016\/S0140-6736(19)32319-0","volume":"394","author":"E Dekker","year":"2019","unstructured":"Dekker E, Tanis PJ, Vleugels JLA, Kasi PM, Wallace MB. Colorectal cancer. Lancet. 2019;394:1467\u20131480.","journal-title":"Lancet"},{"key":"3451_CR2","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/s41392-020-0116-z","volume":"5","author":"Y-H Xie","year":"2020","unstructured":"Xie Y-H, Chen Y-X, Fang J-Y. Comprehensive review of targeted therapy for colorectal cancer. Signal Transduct Target Ther. 2020;5:22.","journal-title":"Signal Transduct Target Ther"},{"key":"3451_CR3","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1128\/MMBR.63.2.405-445.1999","volume":"63","author":"J Zhao","year":"1999","unstructured":"Zhao J, Hyman L, Moore C. Formation of mRNA 3\u2032 ends in eukaryotes: mechanism, regulation, and interrelationships with other steps in mRNA synthesis. Microbiol Mol Biol Rev. 1999;63:405\u2013445.","journal-title":"Microbiol Mol Biol Rev"},{"key":"3451_CR4","doi-asserted-by":"publisher","first-page":"2755","DOI":"10.1101\/gad.11.21.2755","volume":"11","author":"DF Colgan","year":"1997","unstructured":"Colgan DF, Manley JL. Mechanism and regulation of mRNA polyadenylation. Genes Dev. 1997;11:2755\u20132766.","journal-title":"Genes Dev"},{"key":"3451_CR5","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/S0092-8674(00)80057-4","volume":"99","author":"SM Barabino","year":"1999","unstructured":"Barabino SM, Keller W. Last but not least: regulated poly (A) tail formation. Cell. 1999;99:9\u201311.","journal-title":"Cell"},{"key":"3451_CR6","doi-asserted-by":"publisher","unstructured":"Yuan F, Hankey W, Wagner EJ, Li W, Wang Q. Alternative polyadenylation of mRNA and its role in cancer. Genes Dis. https:\/\/doi.org\/10.1016\/j.gendis.2019.10.011 (2019).","DOI":"10.1016\/j.gendis.2019.10.011"},{"key":"3451_CR7","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/nrm.2016.116","volume":"18","author":"B Tian","year":"2017","unstructured":"Tian B, Manley JL. Alternative polyadenylation of mRNA precursors. Nat Rev Mol Cell Biol. 2017;18:18\u201330.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"3451_CR8","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1038\/nrg3482","volume":"14","author":"R Elkon","year":"2013","unstructured":"Elkon R, Ugalde AP, Agami R. Alternative cleavage and polyadenylation: extent, regulation and function. Nat Rev Genet. 2013;14:496\u2013506.","journal-title":"Nat Rev Genet"},{"key":"3451_CR9","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/j.str.2010.12.021","volume":"19","author":"Q Yang","year":"2011","unstructured":"Yang Q, Coseno M, Gilmartin GM, Doublie S. Crystal structure of a human cleavage factor CFI(m)25\/CFI(m)68\/RNA complex provides an insight into poly(A) site recognition and RNA looping. Structure. 2011;19:368\u2013377.","journal-title":"Structure"},{"key":"3451_CR10","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1042\/BST20160078","volume":"44","author":"JG Hardy","year":"2016","unstructured":"Hardy JG, Norbury CJ. Cleavage factor Im (CFIm) as a regulator of alternative polyadenylation. Biochem Soc Trans. 2016;44:1051\u20131057.","journal-title":"Biochem Soc Trans"},{"key":"3451_CR11","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1038\/nature13261","volume":"510","author":"CP Masamha","year":"2014","unstructured":"Masamha CP, Xia Z, Yang J, Albrecht TR, Li M, Shyu AB, et al. CFIm25 links alternative polyadenylation to glioblastoma tumour suppression. Nature. 2014;510:412\u2013416.","journal-title":"Nature"},{"key":"3451_CR12","doi-asserted-by":"publisher","first-page":"420","DOI":"10.3389\/fnmol.2017.00420","volume":"10","author":"JC Lou","year":"2017","unstructured":"Lou JC, Lan YL, Gao JX, Ma BB, Yang T, Yuan ZB, et al. Silencing NUDT21 Attenuates the mesenchymal identity of glioblastoma cells via the NF-kappaB pathway. Front Mol Neurosci. 2017;10:420.","journal-title":"Front Mol Neurosci"},{"key":"3451_CR13","doi-asserted-by":"publisher","first-page":"4887","DOI":"10.1038\/s41388-018-0280-6","volume":"37","author":"S Tan","year":"2018","unstructured":"Tan S, Li H, Zhang W, Shao Y, Liu Y, Guan H, et al. NUDT21 negatively regulates PSMB2 and CXXC5 by alternative polyadenylation and contributes to hepatocellular carcinoma suppression. Oncogene. 2018;37:4887\u20134900.","journal-title":"Oncogene"},{"key":"3451_CR14","doi-asserted-by":"publisher","first-page":"4311","DOI":"10.2147\/CMAR.S173496","volume":"10","author":"L Zhang","year":"2018","unstructured":"Zhang L, Zhang W. Knockdown of NUDT21 inhibits proliferation and promotes apoptosis of human K562 leukemia cells through ERK pathway. Cancer Manag Res. 2018;10:4311\u20134323.","journal-title":"Cancer Manag Res"},{"key":"3451_CR15","doi-asserted-by":"publisher","first-page":"4154","DOI":"10.1038\/s41388-019-0714-9","volume":"38","author":"Y Chu","year":"2019","unstructured":"Chu Y, Elrod N, Wang C, Li L, Chen T, Routh A, et al. Nudt21 regulates the alternative polyadenylation of Pak1 and is predictive in the prognosis of glioblastoma patients. Oncogene. 2019;38:4154\u20134168.","journal-title":"Oncogene"},{"key":"3451_CR16","doi-asserted-by":"publisher","first-page":"7156","DOI":"10.7150\/thno.36030","volume":"9","author":"M Xiong","year":"2019","unstructured":"Xiong M, Chen L, Zhou L, Ding Y, Kazobinka G, Chen Z, et al. NUDT21 inhibits bladder cancer progression through ANXA2 and LIMK2 by alternative polyadenylation. Theranostics. 2019;9:7156\u20137167.","journal-title":"Theranostics"},{"key":"3451_CR17","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.1038\/s41388-021-01693-w","volume":"40","author":"Y Xing","year":"2021","unstructured":"Xing Y, Chen L, Gu H, Yang C, Zhao J, Chen Z, et al. Downregulation of NUDT21 contributes to cervical cancer progression through alternative polyadenylation. Oncogene. 2021;40:2051\u20132064.","journal-title":"Oncogene"},{"key":"3451_CR18","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1038\/s41590-022-01314-y","volume":"23","author":"MT Witkowski","year":"2022","unstructured":"Witkowski MT, Lee S, Wang E, Lee AK, Talbot A, Ma C, et al. NUDT21 limits CD19 levels through alternative mRNA polyadenylation in B cell acute lymphoblastic leukemia. Nat Immunol. 2022;23:1424\u20131432.","journal-title":"Nat Immunol"},{"key":"3451_CR19","doi-asserted-by":"crossref","unstructured":"Tan Y, Zheng T, Su Z, Chen M, Chen S, Zhang R et al. Alternative polyadenylation reprogramming of MORC2 induced by NUDT21 loss promotes KIRC carcinogenesis. JCI Insight. 8.(2023).","DOI":"10.1172\/jci.insight.162893"},{"key":"3451_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2024.108822","volume":"27","author":"Y Zhou","year":"2024","unstructured":"Zhou Y, Yang J, Huang L, Liu C, Yu M, Chen R, et al. Nudt21-mediated alternative polyadenylation of MZT1 3\u2019UTR contributes to pancreatic cancer progression. iScience. 2024;27:108822.","journal-title":"iScience"},{"key":"3451_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2024.101144","volume":"77","author":"SC Lin","year":"2024","unstructured":"Lin SC, Tsai YC, Chen YL, Lin HK, Huang YC, Lin YS, et al. Un-methylation of NUDT21 represses docosahexaenoic acid biosynthesis contributing to enzalutamide resistance in prostate cancer. Drug Resist Updat. 2024;77:101144.","journal-title":"Drug Resist Updat"},{"key":"3451_CR22","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1586\/egh.11.67","volume":"5","author":"S Sweetser","year":"2011","unstructured":"Sweetser S, Smyrk TC, Sugumar A. Serrated polyps: critical precursors to colorectal cancer. Expert Rev Gastroenterol Hepatol. 2011;5:627\u2013635.","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"3451_CR23","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1053\/j.gastro.2019.06.041","volume":"157","author":"SD Crockett","year":"2019","unstructured":"Crockett SD, Nagtegaal ID. Terminology, molecular features, epidemiology, and management of serrated colorectal neoplasia. Gastroenterology. 2019;157:949\u2013966.e944.","journal-title":"Gastroenterology"},{"key":"3451_CR24","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.cell.2014.06.004","volume":"158","author":"DD Shao","year":"2014","unstructured":"Shao DD, Xue W, Krall EB, Bhutkar A, Piccioni F, Wang X, et al. KRAS and YAP1 converge to regulate EMT and tumor survival. Cell. 2014;158:171\u2013184.","journal-title":"Cell"},{"key":"3451_CR25","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1038\/nature15382","volume":"526","author":"A Gregorieff","year":"2015","unstructured":"Gregorieff A, Liu Y, Inanlou MR, Khomchuk Y, Wrana JL. Yap-dependent reprogramming of Lgr5(+) stem cells drives intestinal regeneration and cancer. Nature. 2015;526:715\u2013718.","journal-title":"Nature"},{"key":"3451_CR26","unstructured":"Meseeha M, Attia M. Colon polyps. In: StatPearls (Treasure Island, 2021)."},{"key":"3451_CR27","doi-asserted-by":"publisher","first-page":"E1312","DOI":"10.1073\/pnas.1110428108","volume":"108","author":"D Zhou","year":"2011","unstructured":"Zhou D, Zhang Y, Wu H, Barry E, Yin Y, Lawrence E, et al. Mst1 and Mst2 protein kinases restrain intestinal stem cell proliferation and colonic tumorigenesis by inhibition of Yes-associated protein (Yap) overabundance. Proc Natl Acad Sci USA. 2011;108:E1312\u20131320.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3451_CR28","doi-asserted-by":"publisher","first-page":"11730","DOI":"10.1074\/jbc.M111.327767","volume":"287","author":"WM Konsavage Jr.","year":"2012","unstructured":"Konsavage WM Jr., Kyler SL, Rennoll SA, Jin G, Yochum GS. Wnt\/beta-catenin signaling regulates Yes-associated protein (YAP) gene expression in colorectal carcinoma cells. J Biol Chem. 2012;287:11730\u201311739.","journal-title":"J Biol Chem"},{"key":"3451_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-018-0698-3","volume":"9","author":"MH Choe","year":"2018","unstructured":"Choe MH, Yoon Y, Kim J, Hwang SG, Han YH, Kim JS. miR-550a-3-5p acts as a tumor suppressor and reverses BRAF inhibitor resistance through the direct targeting of YAP. Cell Death Dis. 2018;9:640.","journal-title":"Cell Death Dis"},{"key":"3451_CR30","doi-asserted-by":"crossref","unstructured":"Greenhough A, Bagley C, Heesom KJ, Gurevich DB, Gay D, Bond M et al. Cancer cell adaptation to hypoxia involves a HIF-GPRC5A-YAP axis. EMBO Mol Med. 10 2018;10.","DOI":"10.15252\/emmm.201708699"},{"key":"3451_CR31","doi-asserted-by":"publisher","first-page":"2627","DOI":"10.1038\/s41388-018-0628-y","volume":"38","author":"Z Sun","year":"2019","unstructured":"Sun Z, Ou C, Liu J, Chen C, Zhou Q, Yang S, et al. YAP1-induced MALAT1 promotes epithelial-mesenchymal transition and angiogenesis by sponging miR-126-5p in colorectal cancer. Oncogene. 2019;38:2627\u20132644.","journal-title":"Oncogene"},{"key":"3451_CR32","doi-asserted-by":"publisher","first-page":"4298","DOI":"10.7150\/thno.51342","volume":"11","author":"C Chen","year":"2021","unstructured":"Chen C, Yuan W, Zhou Q, Shao B, Guo Y, Wang W, et al. N6-methyladenosine-induced circ1662 promotes metastasis of colorectal cancer by accelerating YAP1 nuclear localization. Theranostics. 2021;11:4298\u20134315.","journal-title":"Theranostics"},{"key":"3451_CR33","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1158\/1078-0432.CCR-14-1374","volume":"21","author":"KW Lee","year":"2015","unstructured":"Lee KW, Lee SS, Kim SB, Sohn BH, Lee HS, Jang HJ, et al. Significant association of oncogene YAP1 with poor prognosis and cetuximab resistance in colorectal cancer patients. Clin Cancer Res. 2015;21:357\u2013364.","journal-title":"Clin Cancer Res"},{"key":"3451_CR34","doi-asserted-by":"publisher","first-page":"100878","DOI":"10.1016\/j.isci.2020.100878","volume":"23","author":"R Rupaimoole","year":"2020","unstructured":"Rupaimoole R, Yoon B, Zhang WC, Adams BD, Slack FJ. A high-throughput small molecule screen identifies ouabain as synergistic with miR-34a in killing lung cancer cells. iScience. 2020;23:100878.","journal-title":"iScience"},{"key":"3451_CR35","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1038\/s41591-024-03486-6","volume":"31","author":"C Kurzeder","year":"2025","unstructured":"Kurzeder C, Nguyen-Strauli BD, Krol I, Ring A, Castro-Giner F, Nuesch M, et al. Digoxin for reduction of circulating tumor cell cluster size in metastatic breast cancer: a proof-of-concept trial. Nat Med. 2025;31:1120\u20131124.","journal-title":"Nat Med"},{"key":"3451_CR36","doi-asserted-by":"publisher","unstructured":"Li C, Luo P, Tang L, Yang Y, Rao L, Zhong L. Digoxin targets BHLHE40 to inhibit epithelial-mesenchymal transition in cervical cancer cells via downregulation of ANGPTL3. J Nat Med. https:\/\/doi.org\/10.1007\/s11418-025-01947-x (2025).","DOI":"10.1007\/s11418-025-01947-x"},{"key":"3451_CR37","doi-asserted-by":"publisher","unstructured":"Ye ZH, Yu WB, Huang MY, Chen YY, Zhang LL, Leung CH et al. Repurposing cardiac glycosides to potentiate CD47 blockade through calreticulin-mediated phagocytic effects for lung cancer treatment. Adv Sci. https:\/\/doi.org\/10.1002\/advs.202508245:e08245 (2025).","DOI":"10.1002\/advs.202508245:e08245"},{"key":"3451_CR38","doi-asserted-by":"publisher","DOI":"10.1080\/27694127.2023.2256146","volume":"2","author":"JP Campos-Blazquez","year":"2023","unstructured":"Campos-Blazquez JP, Flores-Maldonado C, Gallardo JM, Bonilla-Delgado J, Pedraza-Ramirez AA, Lopez-Mendez O, et al. Ouabain promotes claudin-1, -2, and -4 autophagic degradation through oxidative stress and AMPK activation in MDCK cells. Autophagy Rep. 2023;2:2256146.","journal-title":"Autophagy Rep"},{"key":"3451_CR39","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1080\/15548627.2022.2162244","volume":"19","author":"Y Lu","year":"2023","unstructured":"Lu Y, Chen X, Liu X, Shi Y, Wei Z, Feng L, et al. Endothelial TFEB signaling-mediated autophagic disturbance initiates microglial activation and cognitive dysfunction. Autophagy. 2023;19:1803\u20131820.","journal-title":"Autophagy"},{"key":"3451_CR40","doi-asserted-by":"publisher","first-page":"C263","DOI":"10.1152\/ajpcell.00225.2012","volume":"304","author":"P Chanvorachote","year":"2013","unstructured":"Chanvorachote P, Pongrakhananon V. Ouabain downregulates Mcl-1 and sensitizes lung cancer cells to TRAIL-induced apoptosis. Am J Physiol Cell Physiol. 2013;304:C263\u2013272.","journal-title":"Am J Physiol Cell Physiol"},{"key":"3451_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2019.101131","volume":"22","author":"Y Zhou","year":"2019","unstructured":"Zhou Y, Zhou Y, Yang M, Wang K, Liu Y, Zhang M, et al. Digoxin sensitizes gemcitabine-resistant pancreatic cancer cells to gemcitabine via inhibiting Nrf2 signaling pathway. Redox Biol. 2019;22:101131.","journal-title":"Redox Biol"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03451-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03451-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03451-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T10:17:33Z","timestamp":1785493053000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03451-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,6]]},"references-count":41,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,8,20]]}},"alternative-id":["3451"],"URL":"https:\/\/doi.org\/10.1038\/s41416-026-03451-9","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,6]]},"assertion":[{"value":"7 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"This study was reviewed and approved by the Institutional Review Board of National Cheng Kung University Hospital (approval No. A-ER-106-491). All procedures were performed in accordance with the relevant guidelines and regulations. Written informed consent was obtained from all patients. Colorectal cancer tissues, polyps, and normal colon tissue specimens were collected from patients undergoing surgical resection at the Department of Surgery of a university hospital. The study protocol was approved by the Institutional Review Board, and informed consent was obtained from each participant. No identifiable images from human research participants were used in this study.","order":2,"name":"Ethics","label":"Ethics approval and consent to participate for clinical specimen collection","group":{"name":"EthicsHeading","label":"Ethics"}}]}}